Article

Eplerenone Post Myocardial Infarction Plus Standard Treatment May Prevent Adverse Cardiovascular Outcomes

Authors:
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

Early administration of eplerenone added to standard treatment in postmyocardial infarction patients appears to reduce the risk of adverse cardiovascular outcomes and heart failure, according to results from the Impact of Eplerenone on Cardiovascular Outcomes in Patients Post-Myocardial Infarction trial [REMINDER; NCT01176968].

No full-text available

Request Full-text Paper PDF

To read the full-text of this research,
you can request a copy directly from the authors.

ResearchGate has not been able to resolve any citations for this publication.
ResearchGate has not been able to resolve any references for this publication.